Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1988 Feb;85(4):1052–1056. doi: 10.1073/pnas.85.4.1052

Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

C D Estin 1, U S Stevenson 1, G D Plowman 1, S L Hu 1, P Sridhar 1, I Hellström 1, J P Brown 1, K E Hellström 1
PMCID: PMC279699  PMID: 3422478

Abstract

We have constructed a recombinant vaccinia virus, v-p97NY, which expresses the human melanoma-associated glycoprotein p97. Immunization with v-p97NY could induce humoral and cell-mediated immunity to p97, including delayed-type hypersensitivity, in mice and in two of two monkeys (Macaca fascicularis). The fact that an immune response was induced also in monkeys is important because normal cells from monkeys, but not from mice, express a low level of cross-reactive p97. Mice immunized with v-p97NY rejected transplants of syngeneic mouse melanoma expressing p97. A rejection response could be detected also when immunization was started 2 days after tumor transplantation, irrespective of whether the transplanted cells grew subcutaneously or as lung metastases. Evidence was obtained that melanoma cells lacking p97 may be killed as "bystanders" at the site of an immune response to melanoma cells expressing p97.

Full text

PDF
1052

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albino A. P., Lloyd K. O., Houghton A. N., Oettgen H. F., Old L. J. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med. 1981 Dec 1;154(6):1764–1778. doi: 10.1084/jem.154.6.1764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bagshawe K. D. Third Gordon Hamilton-Fairley Memorial Lecture. Tumour markers--where do we go from here? Br J Cancer. 1983 Aug;48(2):167–175. doi: 10.1038/bjc.1983.172. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bennink J. R., Yewdell J. W., Smith G. L., Moller C., Moss B. Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature. 1984 Oct 11;311(5986):578–579. doi: 10.1038/311578a0. [DOI] [PubMed] [Google Scholar]
  4. Brown J. P., Nishiyama K., Hellström I., Hellström K. E. Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies. J Immunol. 1981 Aug;127(2):539–546. [PubMed] [Google Scholar]
  5. Brown J. P., Woodbury R. G., Hart C. E., Hellström I., Hellström K. E. Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. Proc Natl Acad Sci U S A. 1981 Jan;78(1):539–543. doi: 10.1073/pnas.78.1.539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bystryn J. C. Antibody response and tumor growth in syngeneic mice immunized to partially purified B16 melanoma-associated antigens. J Immunol. 1978 Jan;120(1):96–101. [PubMed] [Google Scholar]
  7. Earl P. L., Moss B., Morrison R. P., Wehrly K., Nishio J., Chesebro B. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science. 1986 Nov 7;234(4777):728–731. doi: 10.1126/science.3490689. [DOI] [PubMed] [Google Scholar]
  8. Fidler I. J., Hart I. R. Biological and experimental consequences of the zonal composition of solid tumors. Cancer Res. 1981 Aug;41(8):3266–3267. [PubMed] [Google Scholar]
  9. Fidler I. J., Poste G. Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol. 1982;5(2):161–174. doi: 10.1007/BF00199794. [DOI] [PubMed] [Google Scholar]
  10. Forstrom J. W., Nelson K. A., Nepom G. T., Hellström I., Hellström K. E. Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody. Nature. 1983 Jun 16;303(5918):627–629. doi: 10.1038/303627a0. [DOI] [PubMed] [Google Scholar]
  11. Greenberg P. D., Kern D. E., Cheever M. A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 1985 May 1;161(5):1122–1134. doi: 10.1084/jem.161.5.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hellström I., Brankovan V., Hellström K. E. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1499–1502. doi: 10.1073/pnas.82.5.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hellström I., Horn D., Linsley P., Brown J. P., Brankovan V., Hellström K. E. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res. 1986 Aug;46(8):3917–3923. [PubMed] [Google Scholar]
  14. Hellström K. E., Hellström I. Cellular immunity against tumor antigens. Adv Cancer Res. 1969;12:167–223. doi: 10.1016/s0065-230x(08)60331-0. [DOI] [PubMed] [Google Scholar]
  15. Hoover H. C., Jr, Surdyke M. G., Dangel R. B., Peters L. C., Hanna M. G., Jr Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer. 1985 Mar 15;55(6):1236–1243. doi: 10.1002/1097-0142(19850315)55:6<1236::aid-cncr2820550616>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  16. Hu S. L., Plowman G. D., Sridhar P., Stevenson U. S., Brown J. P., Estin C. D. Characterization of a recombinant vaccinia virus expressing human melanoma-associated antigen p97. J Virol. 1988 Jan;62(1):176–180. doi: 10.1128/jvi.62.1.176-180.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kennedy R. C., Dreesman G. R., Butel J. S., Lanford R. E. Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving antiidiotypic antibodies. J Exp Med. 1985 Jun 1;161(6):1432–1449. doi: 10.1084/jem.161.6.1432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lathe R., Kieny M. P., Gerlinger P., Clertant P., Guizani I., Cuzin F., Chambon P. Tumour prevention and rejection with recombinant vaccinia. 1987 Apr 30-May 6Nature. 326(6116):878–880. doi: 10.1038/326878a0. [DOI] [PubMed] [Google Scholar]
  19. Lee V. K., Harriott T. G., Kuchroo V. K., Halliday W. J., Hellström I., Hellström K. E. Monoclonal antiidiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity. Proc Natl Acad Sci U S A. 1985 Sep;82(18):6286–6290. doi: 10.1073/pnas.82.18.6286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Mackett M., Smith G. L., Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol. 1984 Mar;49(3):857–864. doi: 10.1128/jvi.49.3.857-864.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Mackett M., Smith G. L., Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A. 1982 Dec;79(23):7415–7419. doi: 10.1073/pnas.79.23.7415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Mora P. T., Parrott C. L., Baksi K., McFarland V. Immunologic selection of simian virus 40 (SV40) T-antigen-negative tumor cells which arise by excision of early SV40 DNA. J Virol. 1986 Sep;59(3):628–634. doi: 10.1128/jvi.59.3.628-634.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Nepom G. T., Hellström I., Hellström K. E. Suppressor mechanisms in tumor immunity. Experientia. 1983 Mar 15;39(3):235–242. doi: 10.1007/BF01955286. [DOI] [PubMed] [Google Scholar]
  24. Nepom G. T., Nelson K. A., Holbeck S. L., Hellström I., Hellström K. E. Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice. Proc Natl Acad Sci U S A. 1984 May;81(9):2864–2867. doi: 10.1073/pnas.81.9.2864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Panicali D., Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A. 1982 Aug;79(16):4927–4931. doi: 10.1073/pnas.79.16.4927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Rose T. M., Plowman G. D., Teplow D. B., Dreyer W. J., Hellström K. E., Brown J. P. Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1261–1265. doi: 10.1073/pnas.83.5.1261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Sharon R., Naor D. The isolation of immunogenic molecular entities from immunogenic and nonimmunogenic tumor homogenates by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Cancer Immunol Immunother. 1984;18(3):203–208. doi: 10.1007/BF00205512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Wallack M. K., McNally K., Michaelides M., Bash J., Bartolucci A., Siegler H., Balch C., Wanebo H. A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO). Am Surg. 1986 Mar;52(3):148–151. [PubMed] [Google Scholar]
  29. Yeh M. Y., Hellström I., Hellström K. E. Clonal variation in expression of a human melanoma antigen defined by a monoclonal antibody. J Immunol. 1981 Apr;126(4):1312–1317. [PubMed] [Google Scholar]
  30. Zarling J. M., Morton W., Moran P. A., McClure J., Kosowski S. G., Hu S. L. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. 1986 Sep 25-Oct 1Nature. 323(6086):344–346. doi: 10.1038/323344a0. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES